Retrospective analysis of differences in annual factor VIII utilization among haemophilia A patients

Finding differences in drug utilization patterns within rare patient populations is challenging without access to a large sample. Our objective was to identify patient and treatment‐related factors associated with differences in annual recombinant factor VIII (rFVIII) utilization in a large cohort o...

Full description

Saved in:
Bibliographic Details
Published in:Haemophilia : the official journal of the World Federation of Hemophilia 2012-03, Vol.18 (2), p.187-192
Main Authors: EPSTEIN, J., XIONG, Y., WOO, P., LI-McLEOD, J., SPOTTS, G.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Age Factors
B domain-deleted
Child
Child, Preschool
Factor VIII - therapeutic use
Full-length FVIII
FVIII
haemophilia
Hemophilia A - drug therapy
Humans
Infant
Insurance, Health - statistics & numerical data
Peptide Fragments
Pharmaceutical Services - statistics & numerical data
prophylaxis
Recombinant Proteins - therapeutic use
Regression Analysis
Retrospective Studies
Severity of Illness Index
United States
utilization
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Finding differences in drug utilization patterns within rare patient populations is challenging without access to a large sample. Our objective was to identify patient and treatment‐related factors associated with differences in annual recombinant factor VIII (rFVIII) utilization in a large cohort of haemophilia A patients. This retrospective analysis utilized a large, US specialty pharmacy dispensing database from January 2006 to September 2009. Differences in median annual FVIII utilization (IU kg−1year−1) by age, severity, treatment regimen, rFVIII product type and health insurance plan were tested using non‐parametric statistics and regression analysis. A total of 1011 haemophilia A patients were included in the overall analysis. Severe haemophilia patients had higher median annual FVIII utilization than mild/moderate patients (P 
ISSN:1351-8216
1365-2516
DOI:10.1111/j.1365-2516.2011.02636.x